What Is Pan Cytokeratin and How Is It Used in Diagnosis?

Pan-cytokeratin is a cocktail of antibodies designed to detect a broad range of keratin proteins, the structural filaments that define epithelial cells. Pathologists use it as a frontline tool in immunohistochemistry to determine whether a tumor is epithelial in origin, which is critical because the vast majority of human cancers are carcinomas that arise from epithelial tissue. The concept is straightforward: if a mysterious-looking tumor lights up with pan-cytokeratin staining, it almost certainly has an epithelial lineage, which immediately narrows the diagnostic possibilities. But the stain’s reliability varies by tumor type, and both false positives and false negatives occur often enough to keep pathologists on their toes.

Why Keratins Matter So Much in Cancer Diagnosis

Keratins are the intermediate-filament proteins made by epithelial cells, the cells that line your skin, organs, and glands. The human genome encodes 54 keratin genes, split into two families (type I and type II), and they are expressed in tissue-specific, context-dependent patterns.¹ This matters because different epithelial tissues produce different combinations of keratins. A liver cell and a lung cell both make keratins, but not the same ones. That specificity is what lets pathologists use individual keratins (like CK7 or CK20) to pin down which organ a cancer likely came from.

Pan-cytokeratin antibodies take a different, broader approach. Instead of targeting one or two specific keratins, they recognize a wide swath of the keratin family at once. The goal is not to identify the organ of origin but to answer a more basic question: is this tumor epithelial at all? That question comes up constantly, because under a microscope, a poorly differentiated carcinoma can look almost identical to a lymphoma, a melanoma, or a sarcoma. Each of those tumor types demands a completely different treatment strategy, so getting the lineage right is the essential first step.

The Antibody Clones Behind the Name

“Pan-cytokeratin” is not a single product. It refers to any antibody or combination of antibodies that covers a broad spectrum of keratins. The most widely used is AE1/AE3, a cocktail of two monoclonal antibodies: AE1 targets most type I keratins and AE3 targets most type II keratins. Together, they cover the majority of keratins found across epithelial tissues. Other common clones include MNF116 and CAM5.2, each with a slightly different keratin coverage profile.

A head-to-head comparison of pan-cytokeratin markers used during Mohs surgery for basal cell carcinoma found that AE1/AE3 performed best, achieving an average staining intensity of about 99% and sensitivity of nearly 100%. MNF116, by contrast, scored well on intensity (about 93%) but had notably lower sensitivity at roughly 57%.² That kind of performance gap means the choice of clone is not trivial. Laboratories pick their pan-cytokeratin antibody based on the clinical context, the tissue types they most commonly encounter, and their own validation data.

What the Largest Studies Show About Pan-Keratin Staining

A massive tissue microarray study analyzed over 13,500 tumor samples spanning 121 different tumor types and subtypes. Pan-keratin staining was positive in about 84% of all tumors tested, with the large majority showing strong staining. Among the 75 tumor types classified as epithelial, the results were striking: 83% of those categories showed pan-keratin positivity in 98% or more of their samples. Almost all adenocarcinomas, squamous cell carcinomas, and urothelial carcinomas fell into this group.³

The tumors that consistently failed to stain were all of mesenchymal or blood-cell origin, which is exactly what you’d expect: sarcomas, lymphomas, and leukemias do not arise from epithelial cells and therefore should not produce keratins.³ The middle ground was occupied by a smaller group of tumors with mixed or unusual differentiation patterns, including neuroendocrine tumors, renal cell carcinomas, and adrenocortical tumors. These had pan-keratin positivity rates that ranged widely, making them trickier to classify with pan-cytokeratin alone.

Sorting Out Undifferentiated Tumors

When a pathologist encounters a tumor that looks undifferentiated under the microscope, the standard practice is to run a small panel of broad-lineage markers. Pan-cytokeratin is almost always the first or second stain in that panel. If the tumor stains positive, it points toward carcinoma. If it stains negative but positive for vimentin, the tumor is likely mesenchymal (a sarcoma). If it picks up CD45, it is probably a lymphoma. If S-100 or melanocytic markers light up, melanoma enters the picture.⁴

This triage step sounds mechanical, and in many cases it is. But the real world is messier than the algorithm. Poorly differentiated tumors can co-express markers from different lineages, or lose the markers they ought to express. That is why pathologists never rely on a single stain; the pan-cytokeratin result is interpreted alongside a panel of other markers and the clinical context.

Cancers of Unknown Primary

Roughly 3 to 5 percent of all cancer diagnoses involve metastatic tumors where the primary site cannot be identified. These cancers of unknown primary (CUPs) pose a real clinical challenge because treatment often depends on knowing where the cancer started. Pan-cytokeratin plays an early role in the CUP workup: confirming that the metastatic deposit is indeed a carcinoma, as opposed to a lymphoma or melanoma that happened to spread to an unusual site.⁵

Once epithelial origin is confirmed, the investigation shifts to organ-specific markers. CK7, CK20, TTF-1, CDX2, PAX8, and others help narrow the field. Immunohistochemistry panels for CUPs have improved considerably over the past decade, with better-validated markers and more systematic approaches to narrowing down the primary site.⁶ Pan-cytokeratin is the gate that opens this entire workflow.

Rapid Lymph Node Assessment During Surgery

During breast cancer surgery, pathologists sometimes need to evaluate sentinel lymph nodes while the patient is still under anesthesia. If cancer cells are found in the lymph node, the surgeon may proceed with a more extensive procedure in the same operation. Speed and accuracy both matter enormously here.

One approach is rapid intraoperative immunohistochemistry using cytokeratin staining. A study comparing methods for detecting metastatic breast carcinoma in sentinel lymph nodes found that rapid cytokeratin staining achieved a sensitivity of 92%, outperforming both frozen sections (80%) and touch preparations (64%).⁷ The advantage is that cytokeratin staining highlights even tiny clusters of epithelial cancer cells that might be missed on a frozen section, where they blend into the surrounding lymphoid tissue.

Distinguishing Mesothelioma From Lung Cancer

One of the trickier differential diagnoses in thoracic pathology is separating malignant mesothelioma from lung adenocarcinoma, because both can present as pleural masses and both look epithelial under the microscope. Pan-cytokeratin stains both tumors, so it does not help here. Instead, pathologists build panels using mesothelial-specific markers (calretinin, CK5/6, WT-1, or D2-40) and carcinoma-specific markers (MOC-31, claudin-4). This targeted panel correctly identifies tumor lineage in the large majority of cases.⁸

Pan-cytokeratin still plays a supporting role in this scenario: it confirms that the tumor is epithelial rather than mesenchymal, which rules out sarcomas that can also involve the pleura. But the real diagnostic heavy lifting is done by the organ-specific and lineage-specific markers layered on top of it.

When Pan-Cytokeratin Fails to Stain a Carcinoma

The most significant limitation of pan-cytokeratin is that some genuine carcinomas lose keratin expression. Sarcomatoid carcinomas are the classic example. These are epithelial cancers that have undergone a transformation making them look and behave more like sarcomas, complete with spindle-shaped cells and loss of typical epithelial markers. In the head and neck, a study of 37 sarcomatoid carcinomas found that only 62% were positive for pan-cytokeratin.⁹ That means more than a third of these carcinomas would be missed if pan-cytokeratin were the only marker used. Similar keratin loss has been documented in sarcomatoid carcinomas of the lung and bladder.¹⁰

Adrenocortical carcinomas present another blind spot. A study comparing adrenocortical carcinomas with renal cell carcinomas found that all 20 adrenocortical tumors tested were negative for cytokeratin.¹¹ A pathologist who relied solely on pan-cytokeratin negativity to exclude carcinoma could be led astray here.

When Non-Epithelial Tumors Express Keratin

The flip side of false negatives is false positives: tumors that are not carcinomas but still light up with pan-cytokeratin. Epithelioid vascular tumors, including epithelioid hemangioendothelioma and epithelioid angiosarcoma, are notorious for this. These blood-vessel-derived tumors can closely resemble carcinomas under the microscope, and some of them express keratin in addition to their expected endothelial markers.¹² A case report of epithelioid angiosarcoma of the parotid gland showed the tumor staining positive for both pan-cytokeratin and p63, markers typically associated with squamous cell carcinoma, while endothelial markers like CD31 confirmed the true vascular origin.¹³

Melanomas, too, can occasionally express non-melanocytic markers including cytokeratins, sometimes while simultaneously losing their conventional melanocytic markers like S-100 or HMB-45.¹⁴ These aberrant expression patterns are uncommon but dangerous diagnostically, because they can lead a pathologist to misclassify a melanoma as a carcinoma. The takeaway is consistent across all these scenarios: pan-cytokeratin is a screening tool, not a standalone diagnosis, and it must always be interpreted within a broader antibody panel.

Newer Antibody Clones for Difficult Cases

The recognition that some carcinomas slip through the AE1/AE3 net has driven interest in alternative or supplementary cytokeratin antibodies. One standout is CK-OSCAR, which targets a broad range of keratins through a different epitope. In a study of 30 metaplastic breast carcinomas, every single case (100%) stained positive for CK-OSCAR, compared with 90% for AE1/AE3, 70% for CK-903, about 63% for CAM5.2, and 50% for CK5/6. Among seven spindle cell carcinomas specifically, CK-OSCAR again achieved 100% sensitivity, while AE1/AE3 detected only six of seven cases.¹⁵

These results suggest that CK-OSCAR could serve as a more reliable single-antibody option for confirming epithelial origin in diagnostically challenging tumors. Whether laboratories adopt it widely depends on cost, validation effort, and how well it performs across their own case mix. For now, most pathology departments still rely on AE1/AE3 as their default pan-cytokeratin, supplementing with additional clones when the initial stain is unexpectedly negative in a tumor that looks epithelial on morphology.

Pan-Cytokeratin in Liquid Biopsy

Beyond tissue sections, pan-cytokeratin has found a role in detecting circulating tumor cells (CTCs) in blood samples. CTCs are cancer cells that have broken away from a solid tumor and entered the bloodstream, where they can seed metastases. Detecting them is technically demanding because they are vastly outnumbered by normal blood cells.

Most CTC detection platforms, including the FDA-cleared CellSearch system, use cytokeratin staining as a core identification step. A cell captured from blood is classified as a CTC if it is positive for cytokeratin, positive for a nuclear stain, and negative for the white blood cell marker CD45. A flow cytometry-based approach demonstrated that using cell size and pan-cytokeratin expression as two discriminators could reliably distinguish blood samples from cancer patients versus healthy donors, without requiring the pre-enrichment step that many platforms rely on.¹⁶

There is a catch, though. Cytokeratin-based detection works best for carcinomas. Sarcomas, which are mesenchymal tumors, do not reliably express cytokeratins. A study investigating CTC detection in sarcoma patients found that combining pan-cytokeratin with an antibody against cell-surface vimentin (CSV) significantly improved CTC enumeration compared with using pan-cytokeratin alone or standard cytokeratins 7 and 8.¹⁷ This echoes the tissue-based theme: pan-cytokeratin is excellent for epithelial-origin cancers but needs reinforcement when the tumor has mesenchymal characteristics.

Technical Factors That Can Throw Off Results

Even a well-validated pan-cytokeratin antibody can underperform if the tissue is not handled properly. Prolonged formalin fixation, for example, can diminish the staining of certain keratins. A study examining the effects of extended fixation on immunohistochemical markers found that cytokeratin 7 and high-molecular-weight cytokeratin both lost immunoreactivity with prolonged fixation times.¹⁸ Most clinical labs have standardized fixation protocols to minimize this issue, but specimens that arrive after a delay or are fixed under suboptimal conditions can yield falsely weak or negative cytokeratin staining. Heat-based antigen retrieval techniques can partially rescue compromised staining, but prevention through consistent processing is better than the cure.

Pan-cytokeratin antibodies also find use outside human medicine. In veterinary pathology, the AE1/AE3 clone has been validated across multiple fish species, demonstrating cross-reactivity in sea bream, goldfish, and rainbow trout, among others.¹⁹ Because keratins are evolutionarily conserved, antibodies raised against human keratins often work in other species, which makes pan-cytokeratin a practical option for veterinary tumor diagnostics where species-specific reagents are scarce.

Digital Pathology and Spatial Analysis

Emerging computational approaches are finding new uses for pan-cytokeratin beyond simple positive-or-negative scoring. In multiplex immunofluorescence, where several antibodies tagged with different fluorescent dyes are applied to the same tissue section, pan-cytokeratin serves as the epithelial cell identifier while other markers flag immune cells, stromal components, or proliferation status. An image analysis pipeline recently described for stroma-rich tumors used pan-cytokeratin (AE1/AE3) conjugated to a fluorescent tag to map the spatial distribution of tumor cells relative to stromal markers like fibronectin and proliferation markers like Ki67.²⁰

In this context, pan-cytokeratin is no longer just answering a diagnostic question. It is providing the spatial scaffold that algorithms use to analyze how tumor cells interact with their microenvironment. The density of immune cells near cytokeratin-positive tumor nests, for example, can carry prognostic information that goes well beyond what traditional immunohistochemistry was designed to deliver. As digital pathology matures, the humble pan-cytokeratin stain is being repurposed as a foundational layer for increasingly sophisticated analyses of tumor biology.